## Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE

## **Avatrombopag (Doptelet)**

- Quantity Limits: Yes, 10 or 15 tablets for CLD
- Duration limit: Yes, 5 days for CLD or 30 days for ITP

**Initiation (new start) criteria**: Non-formulary avatrombopag (doptelet) will be covered on the prescription drug benefit when the following criteria are met:

- Prescribed by Oncologist/Hematologist or Hepatology
- Patient is greater than or equal to 18 years of age
- Patient has a diagnosis of chronic Immune mediated thrombocytopenia (ITP) -AND- Has documented insufficient response to corticosteroid, immunoglobulins, rituximab, or eltrombopag -AND- platelet count less than 30 x 10<sup>9</sup>/L -OR-
- Thrombocytopenia of chronic liver disease (CLD) with invasive planned procedure with significant risk bleeding risk -AND- platelet count below 50 x 10<sup>9</sup>/L

<u>Criteria for current Kaiser Permanente members already taking the medication who</u> <u>have not been reviewed previously</u>: Non-formulary avatrombopag (doptelet) will be covered on the prescription drug benefit when the following criteria are met:

- Prescribed by Oncologist/Hematologist or Hepatology
- Patient is greater than or equal to 18 years of age
- Patient has diagnosis of either chronic immune mediated thrombocytopenia (ITP)

<u>Criteria for new members entering Kaiser Permanente already taking the</u> <u>medication who have not been reviewed previously</u>: Non-formulary avatrombopag (doptelet) will be covered on the prescription drug benefit when the following criteria are met:

- Prescribed by Oncologist/Hematologist or Hepatology
- Patient is greater than or equal to 18 years of age
- Patient has diagnosis of either chronic immune mediated thrombocytopenia (ITP)

kp.org

Revised: 05/30/2024 Effective: 08/15/2024 All plans offered and underwritten by Kaiser Foundation Health Plan of the Northwest

